Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
C4 Therapeutics Inc is a biotechnology business based in the US. C4 Therapeutics Inc shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics Inc employs 146 staff and has a trailing 12-month revenue of around $31.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $3.14 |
|---|---|
| 52-week range | $3.00 - $26.80 |
| 50-day moving average | $5.58 |
| 200-day moving average | $8.12 |
| Wall St. target price | $22.42 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.52 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.14 from 2023-03-31
| 1 week (2023-03-24) | -11.30% |
|---|---|
| 1 month (2023-03-01) | -37.76% |
| 3 months (2022-12-30) | -46.78% |
| 6 months (2022-09-30) | -64.20% |
| 1 year (2022-04-01) | -87.47% |
|---|---|
| 2 years (2021-04-01) | -91.87% |
| 3 years (2020-03-28) | N/A |
| 5 years (2018-03-28) | N/A |
| Revenue TTM | $31.1 million |
|---|---|
| Gross profit TTM | $-86,745,000 |
| Return on assets TTM | -17.27% |
| Return on equity TTM | -37.76% |
| Profit margin | 0% |
| Book value | $5.91 |
| Market capitalisation | $152.1 million |
TTM: trailing 12 months
We're not expecting C4 Therapeutics Inc to pay a dividend over the next 12 months.
Over the last 12 months, C4 Therapeutics Inc's shares have ranged in value from as little as $2.995 up to $26.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics Inc's is 2.2457. This would suggest that C4 Therapeutics Inc's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put C4 Therapeutics Inc's beta into context you can compare it against those of similar companies.
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.